Showing posts with label Health. Show all posts
Showing posts with label Health. Show all posts

Palm Sugar – Cheap, Healthy, Delicious! by Evan Huang Yong

Monday, April 11, 2011
I tasted palm sugar in Thailand , almost like a floral scent of sweetness in my pad thai. I could only compare the taste of caramel, although more complex and nectar-like.

Thai cuisine is based on a Chinese concept of incorporating five fundamental flavors in each dish: hot or pungent, salty, sour, fat, and sweet. Because palms grow in India and Thailand , their sap is a natural choice for sweetening foods.

Four years after my trip to Bangkok , walking through the market of Hong Kong to Houston, I noticed a large jar of golden dough with the label "Pure Sugar Palm … fresh natural juice from the coconut flower." I've been avoiding refined cane sugar for five years because it is insanely high glycemic index and the lack of nutritional value. I learned to cook with honey, molasses, sorghum, brown rice syrup, agave nectar, dehydrated cane juice. But I had never seen palm sugar for sale before. I bought the 4-lb. jar to just over $ 6.00, and occasional spoonfuls tasted on the trip back to Arkansas (delicious but not very wise!).

Upon returning home I began to search palm sugar and realized that its glycemic index is 35, just over 1 / 3 the glycemic index of cane sugar (GI 93). This means that that if a person sits down to a tablespoon of palm sugar and a tablespoon of white cane sugar, cane sugar will increase the levels of glucose in the blood of the person to a certain extent, while palm sugar levels will only increase of glucose to about 37% of the level of sugar cane.

What great news for anyone interested to keep their glucose levels, including those with diabetes and those trying to prevent diabetes in their lifetime.

Why palm sugar breaks down more slowly than sugar cane, and thus raises blood glucose levels that cause only% sugar cane, sugar palm requires less insulin to the body to maintain homeostasis . Thus, taxes palm sugar pancreas less than cane sugar. Excessive demand on the pancreas from foods high glycemic exhausts the capacity of the pancreas to produce insulin, as well as the ability of insulin receptors' to recognize insulin, and therefore leads to type II diabetes.

As anyone with a diagnosis of type II diabetes can be said, putting as little pressure as possible on the pancreas is a wise diet. Why palm sugar puts half a lot of pressure on the pancreas, such as white sugar can, we can hazard that the moderate use of Palm sugar is a safe alternative sweetener. By contrast the honey has a GI of 83. Maple syrup has a glycemic index of 54.

ranges Agave nectar glycemic index between 11 and 30, making it the only sweetener glycemic lower than that of palm sugar that I can find.

The relatively low cost of palm sugar, if purchased through major Asian markets, and the presence of natural potassium, magnesium, zinc and iron, make it an economically viable natural sweetener with a pleasant flavor of white sugar.

5 Reasons to Be Bullish About America in Long Run

Thursday, April 7, 2011
1) The United States is the home of the entrepreneur.

2) The United States is the most open/flexible society the world has ever seen.

3) The brightest minds from around the world dream of coming to the United States.

4) English is the universal language.

5) Americanization remains a powerful and growing – though resented – economic and social trend throughout the world. (To quote the advertising/marketing giant WPP Group’s CEO, Sir Martin Sorrell, “Globalization is a misnomer. The better word is Americanization.”)

MinnPost – Questions raised about UW research group’s ‘cozy’ relationship with Big Pharma

Questions raised about UW research group’s ‘cozy’ relationship with Big Pharma

By Susan Perry | Published Wed, Apr 6 2011 8:17 am

As part of its excellent ongoing “Side Effects” series, the Milwaukee Journal Sentinel published an article last weekend that serves as yet another cautionary tale about universities, medicine and financial conflicts of interest.

The central player in this story is a University of Wisconsin pain research group, which has been “a quiet force in the effort to liberalize the way [narcotic painkillers] are prescribed and viewed in the United States,” according to Journal Sentinel reporter John Fauber.

And those efforts have paid off. “Throughout the 1990s and 2000s, as doctors became more willing to prescribe opioid analgesics for chronic conditions such as back pain, headache, and fibromylagia,” writes Fauber, “prescriptions soared, though there are serious doubts about whether the drugs are beneficial for such conditions. Pain specialists say there has been a lack of research showing that the drugs are safe and effective for treating non-cancer pain for many months or years.”

Yet, as the Journal Sentinel’s investigation reveals, the UW Pain & Policy Studies Group and two of its top officials have repeatedly argued (in medical journals, before the U.S. Food and Drug Administration, while serving on medical panels that advise physicians, and elsewhere) against tightening the prescribing rules for these drugs.

Financial incentive
They have a strong incentive to stay on that side of the argument. For during the time the UW pain research group and its officials have been advocating for more liberal prescribing policies for narcotic painkillers, they’ve also continued their “cozy personal financial relationships” with companies manufacturing these drugs — relationships that haven’t always been disclosed, Fauber reports.

“The narcotic painkiller industry’s funding of the UW Pain Group is a unique twist on the drug and medical device industry’s use of medical schools to sell more of its products, sometimes at the expense of patients,” writes Fauber.

A lot of money is at stake, of course. Sales of just one prescription painkiller, OxyContin (made by Purdue Pharma, which has given money to the UW pain research group) reached $3 billion in 2010.

Unintentional overdose deaths have risen
But lives are also on the line, as underscored by statistics presented in the Journal Sentinel article:

* Unintentional overdose deaths from opioid painkillers grew from 2,901 in 1999 to 11,499 in 2007 — more than such deaths from heroin and cocaine combined. As Fauber reports, “Opioid deaths follow a track that is almost identical to the growth in sales of the drugs.”

* In 2007, so many opioid painkillers were being prescribed that a three-week dosing of Vicodin could be given, writes Fauber, to “every man, woman and child round-the-clock … for three weeks.”

Plaintiffs appeal against court ruling over Iressa drug side effects › Japan Today

Plaintiffs seeking compensation over side effects from the lung cancer drug Iressa of British pharmaceutical maker AstraZeneca PLC filed an appeal Wednesday against last month’s Tokyo District Court decision which ordered that damages be paid only to some of the complainants.

The appeal, filed with the Tokyo High Court, rejects the lower court ruling, in which the government and the Japanese subsidiary of the British firm were ordered to pay a total of 17.6 million yen to two of the four plaintiffs, for failing to compensate all plaintiffs.

The Japanese government and AstraZeneca KK have already appealed the district court ruling.

Four bereaved family members of three patients filed the damages suit seeking a combined payment of 77 million yen in compensation from the state and AstraZeneca.

On March 23, the Tokyo District Court ordered the government and AstraZeneca to pay two of the plaintiffs, ruling that AstraZeneca did not sufficiently explain the side effects in a note attached to the drug and that the government failed to instruct the company to include in the note the possibility that a side effect could be fatal when it approved the drug in July 2002.

The court rejected the claims of the two other plaintiffs who are family members of a patient who began taking Iressa after emergency drug safety information on the product was issued on Oct 15, 2002.

Merck fails to get approval to market Gardasil to women older than 27 for protection against HPV virus

Federal drug regulators failed to grant Merck approval to expand the use of its cervical-cancer vaccine Gardasil to older women, the company said in a statement posted on its website.

Merck, which is based in Whitehouse Station, had sought approval from the Food and Drug Administration to market the vaccine to women between the ages of 27 and 45.

CHART: International Public Opinion on Capitalism


The chart above is from today’s online version of The Economist, showing an international comparison of public opinion on the free market, with some interesting results:

1. Brazil ranks #1 for responding “strongly agree” that the free-market system is the best, and Germany ranks #1 for “strongly or somewhat agree.”

2. Germany, Brazil, China and Italy are rank higher than the U.S. for the top two most favorable responses.

3. Citizens of Germany and Italy view free-markets more favorably than the Brits, and a lot more favorably than the French.

4. Japan ranks lowest for the most favorable response (strongly agree).

Questions raised about UW research group’s ‘cozy’ relationship with Big Pharma

Questions raised about UW research group’s ‘cozy’ relationship with Big Pharma

By Susan Perry | Published Wed, Apr 6 2011 8:17 am

As part of its excellent ongoing “Side Effects” series, the Milwaukee Journal Sentinel published an article last weekend that serves as yet another cautionary tale about universities, medicine and financial conflicts of interest.

The central player in this story is a University of Wisconsin pain research group, which has been “a quiet force in the effort to liberalize the way [narcotic painkillers] are prescribed and viewed in the United States,” according to Journal Sentinel reporter John Fauber.

And those efforts have paid off. “Throughout the 1990s and 2000s, as doctors became more willing to prescribe opioid analgesics for chronic conditions such as back pain, headache, and fibromylagia,” writes Fauber, “prescriptions soared, though there are serious doubts about whether the drugs are beneficial for such conditions. Pain specialists say there has been a lack of research showing that the drugs are safe and effective for treating non-cancer pain for many months or years.”

Yet, as the Journal Sentinel’s investigation reveals, the UW Pain & Policy Studies Group and two of its top officials have repeatedly argued (in medical journals, before the U.S. Food and Drug Administration, while serving on medical panels that advise physicians, and elsewhere) against tightening the prescribing rules for these drugs.

Financial incentive
They have a strong incentive to stay on that side of the argument. For during the time the UW pain research group and its officials have been advocating for more liberal prescribing policies for narcotic painkillers, they’ve also continued their “cozy personal financial relationships” with companies manufacturing these drugs — relationships that haven’t always been disclosed, Fauber reports.

“The narcotic painkiller industry’s funding of the UW Pain Group is a unique twist on the drug and medical device industry’s use of medical schools to sell more of its products, sometimes at the expense of patients,” writes Fauber.

A lot of money is at stake, of course. Sales of just one prescription painkiller, OxyContin (made by Purdue Pharma, which has given money to the UW pain research group) reached $3 billion in 2010.

Unintentional overdose deaths have risen
But lives are also on the line, as underscored by statistics presented in the Journal Sentinel article:

* Unintentional overdose deaths from opioid painkillers grew from 2,901 in 1999 to 11,499 in 2007 — more than such deaths from heroin and cocaine combined. As Fauber reports, “Opioid deaths follow a track that is almost identical to the growth in sales of the drugs.”

* In 2007, so many opioid painkillers were being prescribed that a three-week dosing of Vicodin could be given, writes Fauber, to “every man, woman and child round-the-clock … for three weeks.”

WHO YOU GONNA BELIEVE? ( american psychiatric association)

Wednesday, April 6, 2011
American psychiatric association

Ghostwriting Charges and Stonewalling at the American Psychiatric Association

The American Psychiatric Association came under a searchlight this past December over allegations of ghostwriting. The story originated with a public letter from Project on Government Oversight (POGO) to the Director of NIH, and it was picked up by Duff Wilson writing in the New York Times. The book was Recognition and Treatment of Psychiatric Disorders: A Psychopharmacology Handbook for Primary Care. The named authors were Charles Nemeroff, now chairman of psychiatry at the University of Miami, and Alan Schatzberg, formerly chairman of psychiatry at Stanford University. Both are well known for ethical controversy – see here and here. Soon, these allegations were being dissected in the blogosphere, with stellar contributions from Daniel Carlat, 1boringoldman, Ed Silverman, and Alison Bass.

The APA and its publishing arm, known as American Psychiatric Press, Inc. or APPI, came to the defense of the two prominent academic authors over the ghostwriting charge. In particular, an APA employee named Mark Moran authored a denial of the charge in the January 2011 issue of the APA news magazine, Psychiatric News. As the controversy played out, letters from attorneys demanded retractions, and partial qualifications of the original story appeared in the New York Times and on the POGO weblog. There was never any doubt that the heavy lifting was done by a pair of professional writers employed by a medical communications company under a financial grant from a drug company. Nemeroff defended his role by averring that he ‘scrutinized’ the work product of the professional writers. Threatening letters from lawyers for Nemeroff and Schatzberg were publicized, and the APA weighed in.

The coup de grĂ¢ce was administered by blogger Daniel Carlat’s withering review of the book’s artful construction to highlight the use of the sponsoring company’s antidepressant and anti-anxiety drug in primary care, while muting important information about the drug’s liabilities. Nevertheless, the APA held to its legalistic stance in defense of the ‘authors.’ This behavior is counterproductive for professional medical organizations, as I have discussed before, because it misses the ethical forest for the legal trees.

Now comes the good part. In response to the piece by Mark Moran in Psychiatric News, Leemon McHenry prevailed on Robert Rubin and myself to write with him to the magazine’s editors. Leemon is a faculty member in the Department of Philosophy at California State University, Northridge. He also has experience evaluating legal documents arising in litigation over antidepressant drugs. Robert Rubin has partnered with me in outing several notable ethics compromises involving Nemeroff and Schatzberg, going back as far as 2002, though we always call ourselves equal opportunity critics.

Our letter sent in late January to Dr. Carolyn Robinowitz, the Interim Editor of Psychiatric News, has been posted today on the POGO site. In our letter, we challenged much of Mr. Moran’s defense, and we called attention to what WASN’T in the public domain, despite all the claims and counterclaims. Essentially, the partial qualifications of the original reports that appeared in The New York Times and in the letter to NIH from POGO resulted from the inconclusiveness of some of the documents. We called on the APA to come clean with the release of all relevant materials, in the interest of transparency.

For instance, what WASN’T known were the specifics of the contract involving the corporation, the (ahem) authors, the publisher (APPI), and the medical communications company. Or the money flow to the ‘authors’ from the contract in addition to their royalties. Or the legal release form transferring ownership of the work product to the ‘authors’ and APPI. Or the corporation’s planned marketing activities, given that the corporation ordered 10,000 copies of the book. Or the correspondence among all parties that might reveal who actually did what.

Leemon McHenry’s perspective is that this hidden layer of documents may well be available if they could be unsealed in pending litigation. Naturally, corporations and their attorneys strive to keep the information hidden. But our general point is that the APA has a different duty – which is to transparency rather than to stonewalling. Did the APA do that? Sadly, no, they did not. Here is the curt reply from the Executive Editor Catherine Brown denying publication of our letter after a delay of almost 8 weeks. Now that’s what I call stonewalling.

How to correct imbalances


When we eat we rarely consider the effects of food on our bodies, thinking all foods are equally nutritious and none cause harm to our bodies. Little do we know that quantity and quality of what we consume can create a health balance, homeostasis, which maintains good health or an imbalance, which lays the foundation for disease. To a certain extent, we can control the outcome of our health by practicing awareness; making good food choices: and embracing hygienic lifestyle habits.

Our immune systems and the core of our bodies try to maintain an inner balance with a nutritious diet, moderate exercise and mental and emotional stability. Overeating in large quantities causes obesity, which in turn results in excesses, lethargy, immobility, inflammation, strained organs, low metabolism and disease. Under-eating, too, leads to undernourishment, which precipitates nutrient deficiencies, low energy and immunity, irritability, organ failures, depression and disease. Moreover, suboptimal quality and choices of foods invite myriads of inexplicable disorders and misery. How to maintain this delicate equilibrium and how you plan for it require attentiveness to the types of foods consumed.

The health state of the human body can be gauged by the pH balance of the blood. This scale has a range, starting from 0, which is extremely acid, to 14, which are very alkaline, making 7 neutral. This balance is seen in water, which is a neutral 7. Either end of the spectrum means a tipped balance, which results in physical, mental, or emotional disorder. However, the perfect pH level is a measure of 7.2 up to 7.4, which is more on the alkaline side and called a state of homeostasis. This desired median is a predictor of balanced health, energy and wellness, whereas both extremes lead to a selection of disorders and suffering.
 

Histats